Literature DB >> 2258909

12th C. L. Oakley lecture. Pathogenesis of Clostridium difficile infection of the gut.

S P Borriello1.   

Abstract

On the basis of the above findings it is possible to propose a sequence of events following exposure to C. difficile. Exposure of neonates to C. difficile leads to transient colonisation which is almost invariably asymptomatic; the reasons why colonisation is asymptomatic are not known. Exposure of antibiotic-treated adults to C. difficile does not invariably lead to colonisation; however, in those instances where colonisation occurs, it may be transient and asymptomatic or transient and symptomatic. The transient nature of the colonisation could be because the infecting strain is poorly virulent, or because the degree of compromise of the intestinal flora is insufficient to permit establishment and full expression of virulence. It is likely that it is easier to fully compromise the intestinal flora of the elderly so that they more readily become fully susceptible to colonisation by C. difficile. In a fully susceptible host and with a highly virulent strain, the following sequence of events could occur. The organism may associate with the intestinal mucosa possible via fimbriae, and form a microcolony of capsulate cells protected by a glycocalyx. The toxins, or other factors, produced may facilitate the interaction with mucosa and toxin A will result in increased vascular and mucosal permeability resulting in intra-luminal accumulation of serum-albumin-rich fluid. Although C. difficile does not appear to be capable of using serum albumin nutritionally, it may utilise other serum proteins, and the serum proteins in general may compete with host proteases and help prevent degradation of the toxins produced.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1990        PMID: 2258909     DOI: 10.1099/00222615-33-4-207

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  16 in total

1.  Phenotypic and genotypic diversity of the flagellin gene (fliC) among Clostridium difficile isolates from different serogroups.

Authors:  A Tasteyre; T Karjalainen; V Avesani; M Delmée; A Collignon; P Bourlioux; M C Barc
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 2.  Virulence factors in anaerobic bacteria.

Authors:  T Hofstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-11       Impact factor: 3.267

3.  Clostridium difficile infection of the gut.

Authors:  A P Dodson; S P Borriello
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

4.  Nonspecific binding of Clostridium difficile toxin A to murine immunoglobulins occurs via the fab component.

Authors:  D L Cooke; S P Borriello
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

Review 5.  Colonization resistance.

Authors:  E J Vollaard; H A Clasener
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

6.  Bacteriophage-mediated toxin gene regulation in Clostridium difficile.

Authors:  Revathi Govind; Govindsamy Vediyappan; Rial D Rolfe; Bruno Dupuy; Joe A Fralick
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

7.  PCR ribotyping and arbitrarily primed PCR for typing strains of Clostridium difficile from a Polish maternity hospital.

Authors:  G Martirosian; S Kuipers; H Verbrugh; A van Belkum; F Meisel-Mikolajczyk
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

Review 8.  Hypervirulent strains of Clostridium difficile.

Authors:  Barry Cookson
Journal:  Postgrad Med J       Date:  2007-05       Impact factor: 2.401

Review 9.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 10.  Clostridium difficile Infection in Children: Current State and Unanswered Questions.

Authors:  Pranita D Tamma; Thomas J Sandora
Journal:  J Pediatric Infect Dis Soc       Date:  2012-07-25       Impact factor: 3.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.